[Evaluation of the therapeutic
effectiveness of a piracetam plus
dihydroergocristine combination in the treatment
of vertigo]
Lopez Martinez R
Acta Otorrinolaringol Esp (Spain) Jul-Aug 1988,
39 (4) p287-8.
No abstract.
[Treatment of vertigo syndrome with
Nootropil]
Miszke A; Rapacz K
Otolaryngol Pol (Poland) 1988, 42 (5) p312-7.
No abstract.
The
efficacy of piracetam in vertigo. A double-blind
study in patients with vertigo of central
origin.
Oosterveld WJ
Arzneimittelforschung (Germany, West) 1980, 30
(11) p1947-9.
In a double-blind trial according to a
switchback design with 4 periods of one week each
a comparison was made between the effects of
piracetam and a placebo. In 22 patients with
vertigo of central origin (posttraumatic,
psychogenic, ecileptogenic and hypertensive
vertigo were excluded) piracetam was found to
significantly reduce symptoms. On anamnestic
examination the patients noted the effect of both
substances on vertigo, motility disturbances,
vitality and sleep. Piracetam was found to have a
significant effect on the first three. The effect
of piracetam is explained by an enhanced control
of the cerebral cortex on the subordinated
vestibular centers, in agreement with findings in
the literature on animal and human
pharmacology.
The
balancing outcome of a pharmacological treatment
by vertiginous patients
Rocher F.P.
Dr. F.P. Rocher, Rotova 50, 46700 Gandia
(Valencia) Spain
Anales Otorrinolaringologicos Ibero-Americanos
(Spain) 1999, 26/3 (271-291)
From the age of sixty, vertigo is mainly due to
vertebro-basilar insufficiency. It has been
described that the association of
Dihydroergocristine-Piracetam (D-P) is a usefull
treatment for vertebro- basilar insufficiency.
That is why we have designed a comparative study
between D-P an a Placebo, so that prove if this
association can be usefull in the treatment of
vertigo occassionated by cerebrovascular
insufficiency. Fifty patients complaining of
vertigo were included in the study after an
untreatment term. 19 received a daily capsule of
Placebo, and the other 31, treated with D-P, were
divided in two groups: 16 patients received a dose
of 3 mg Dihydroergocristine + 1,6 g Piracetam
every 12 hours per os; and 15 other were treated
with 1,5 mg Dihydroergocristine + 0,8 g Piracetam
every 8 hours during 90 days. The patients were
evaluated at the beginning of the study and 90
days later, with anamnesis and vestibular tests.
In the last consultation the patients
autoevaluated themselves the effect and the
tolerance to the drugs received. In the Placebo
group it was observed an improvement or
disappearance of vertiginous symptoms in the 68,5%
of the cases, while with D-P was 93,7% at the dose
of 3 mg Dihydroergocristine + 1,6 Piracetam each
12 hours and 100% with the dose 1,5 mg
Dihydroergocristine + 0,8 Piracetam each 8 hours.
None of the treated patients with D-P worsened
their symptoms. We observe a considerable decrease
in the number of patients with vegetative symptoms
in the group treated with D-P related to the
Placebo group, though the symptoms persisted more
time in the group treated with D-P that in the
Placebo group. The group treated with D-P get a
higher percentage of improvements and
disappearance of auditive and cervical symptoms
that the group treated with Placebo. In the
vestibulo-spinal and cerebellous tests it was
observed a better improvement with D-P at the dose
of 1,5 mg of Dihydroergocristine + 0,8 g Piracetam
each hours compared with the other two groups. It
can be concluded that the association D-P is an
effective treatment for vertigo, getting also a
higher normalization of the vestibular tests than
Placebo.
Dizziness
and dizzy feeling in the elderly:
Treatment
Marquet T.; Belmin J.
J. Belmin, Serv. Medecine Interne Geriatrique,
Hopital Rene Muret-Bigottini, 93720 Sevran
France
Revue de Geriatrie (France) 1997, 22/7
(457-462)
No abstract.
Disabling
acute vertigo attack
Moussalle S.
Servicio de Otorrinolaringologia, Faculdade de
Medicina, Pontificia Universidade Catolica,Rio
Grande Do Sul Brazil
Revista Brasileira de Otorrinolaringologia
(Brazil) 1994, 60/4 (326)
No abstract.
Vertigo
Gananca M.M.; Caovilla H.H.; Gananca F.F.; De
Toledo Piza Peluso E.
Rua Dr. A. de Campos Rodrigues, 309,CEP
04544-000, Sao Paulo Brazil
Revista Brasileira de Medicina (Brazil)
1993/1994, 50/Spec. Iss. Dec. (193-202)
The importance of the neurootological
evaluation was justified in order to establish the
adequate diagnosis for the adequate therapy. Very
good results can be obtained in the treatment of
vertigo by the use of drugs, rehabilitation
exercises and nutritional diets. Surgery is
indicated in some particular cases.
Hemorheologic therapy of vertigo
Spurk P.; Dehnert H.G.; Angelkort B.
St. Vincenzkrankenhaus, D-5750 Menden 1
Germany
Vasa - Journal of Vascular Diseases (Switzerland)
1991, 20/Suppl. 33 (169-170)
Hemorheological treatment in vertigo. Depending
on data of hemorheology disturbances in risk
factors and carotid artery
artherosclerosis-progression in vertigo on
non-vestibular origin this study evaluates
treatment effects by basis, i.e. correction of
risk factors only, versus additional
hemorheological treatment (Lowering hct., HAES,
Pentoxifylline). Patients: N = 88 fe.51 m 37 age
25-86 mean 65.1. Results: ++ base gr. 35% hemorh.
62% + base gr. 40% hem. 38% no effect base gr. 25%
hemorh. none.
Vertigo,
dysarthria and hemiparesis in a 71 year-old
woman
Vespignani H.; Defer G.; Gray F.
Service de Neurologie, Nancy France
Revue Neurologique (France) 1991, 147/11
(752-758)
No abstract.
Drugs
for dizziniess; exploitation of medical
incapability
Van Gijn J.
Vakgroep Neurologie, Academisch Ziekenhuis,
Postbus 85500, 3508 GA Utrecht Netherlands
Nederlands Tijdschrift voor Geneeskunde
(Netherlands) 1991, 135/14 (599-603)
No abstract.
Vertigo
syndrome treatment by nootropil
Miszke A.; Rapacz K.
Oddzial Otolaryngologiczny KSZ im G. Narutowicza,
Krakow Poland
Otolaryngologia Polska (Poland) 1988, 42/5
(312-317)
No abstract.
Clinic
assay on the assocation piracetam and
dihydroergocristine in vertigo of several
etiologies
Ordosgoitia H.; Castro C.; Carbayeda M.;
Labella T.
Facultad de Medicina, Catedra de O.R.L., 15704
Santiago de Compostela Spain
Anales Otorrinolaringologicos Ibero-Americanos
(Spain) 1989, 16/3 (271-279)
No abstract.
Treatment of vertigo with piracetam:
Comparison with placebo in 50 cases
Haguenauer J.-P.
Gazette Medicale (France) 1986, 93/28 (67-70)
No abstract.
Current
concepts in management
Oosterveld W.J.
Vestibular Department, Ear, Nose and Throat
Clinic, Academisch Medisch Centrum, Amsterdam
Netherlands
Drugs (Australia) 1985, 30/3 (275-283)
Vertigo is not a disease, but a symptom. The
management of vertigo requires more than the
treatment of the symptom alone, as it concerns the
whole physical and psychological condition of the
patient. In addition to causal treatment,
symptomatic treatment is needed in many cases.
This specific treatment consists of vestibular
exercises and drug therapy. The efficacy and use
of the different drugs available are
discussed.
The
effect of piracetam (Nootropil, UCB 6215) upon the
late symptoms of patients with head
injuries
Aantaa E.; Meurman O.H.
Otolaryngol. Univ. Clin., Turku Finland
Journal of International Medical Research 1975,
3/5 (352-355)
Sixty patients whose head injuries had occurred
2-6 mth previously were examined in a double blind
trial to demonstrate the effect of piracetam (UCB
6215) upon late symptoms. A significantly better
result of treatment of vertigo was established in
the piracetam group compared to the placebo group.
The disappearance of symptoms of vertigo could
also be objectively established by diminished
spontaneous and positional nystagmus as well as
diminished pendel deviations with eyes closed. No
significant change during the period of treatment
could be established with respect to the caloric
test.
Piracetam in patients with chronic
vertigo. Results of a
double-blind,placebo-controlled study
Rosenhall U.; Deberdt W.; Friberg U.; Kerr A.;
Oosterveld W.
UCB Pharma, International Development, Chemin du
Foriest, B-1420 Braine-l'Alleud Belgium
Clinical Drug Investigation (New Zealand), 1996,
11/5 (251-260)
The nootropic agent piracetam, which exerts
diverse effects through actions on cerebral
neurotr reported to alleviate vertigo. We
performed a multicentre, double-blind,
placebo-controlled study to assess the efficacy
and tolerability of piracetam 800 mg 3 times daily
orally for 8 weeks. The study group consisted of
143 middle-aged and elderly outpatients of ear,
nose and throat clinics who had suffered from
vertigo for at least 3 months, had experienced at
least 3 episodes per month, and the vertigo was
severe enough to disrupt daily life. Primary
outcome measures were patient self-evaluations of
vertigo: the frequency of episodes, and their
severity using visual analogue scales (VAS).
Malaise and imbalance between episodes (VAS), the
effect of vertigo on walking (VAS), the duration
of incapacity, and overall evaluations by patients
and investigators were also assessed. On entry,
episodes were more frequent (p< 0.05) and
malaise between episodes more severe (p < 0.05)
in the piracetam group. Data were not evaluable in
54 patients because of either adverse events (12
piracetam, 12 placebo) or protocol deviations. An
intention-to-treat analysis showed that episodes
of vertigo were less frequent (p < 0.03) but
not less severe on piracetam than on placebo:
interval malaise (p < 0.05) and imbalance (p
< 0.01) improved more and the duration of
incapacity was less (p < 0.05). These changes,
which were maximal after 8 weeks' medication, had
almost disappeared 4 weeks after the end of
treatment. Tolerance to piracetam was good, with
few drug-related adverse events occurring. These
findings provide further evidence that piracetam
alleviates vertigo by reducing the frequency of
episodes, the severity of malaise and imbalance
between episodes, and the duration of associated
incapacity.
Nootropics: Efficacy and tolerability
of products from three active substance
classes
Letzel H.; Haan J.; Feil W.B.
STATICON Medizinische, Forschunsgesellschaft mbH,
Behringstrasse 12, D-82152 Planegg Germany
Journal of Drug Development and Clinical Practice
(United Kingdom), 1996, 8/2 (77-94)
This paper reviews and evaluates all the
currently available clinical trials on the
efficacy of three nootropics. Only randomised,
double-blind, placebo-controlled clinical trials
were taken into account which produced 44 studies
allowing comparison of the patient populations,
efficacy and tolerability of Ginkgo biloba special
extracts, nimodipine and tacrine. Taking all the
studies together, statistically significant
results were obtained at three relevant levels of
efficacy (psychopathological, psychometric,
behavioural) for all three substances. Nine
studies produced significant results at all three
efficacy levels. One study on Ginkgo biloba and
one on tacrine also produced significant
rerationalised diagnosis of dementia, inclusion of
mild-to-moderate cases, statistical proof at all
three levels of efficacy and global clinical
evaluation). The clinical efficacy of all three
substances has thus been demonstrated.
The
effect of ginkgo biloba glycoside on the blood
viscosity and erythrocyte
deformability
Erdincler D.S.; Karakoc Y.; Toplan S.; Onen S.;
Sukyasyan A.; Beger T.; Demiroglu C.
Gerontology Division, Department of Internal
Medicine, I.U. Cerrahpasa Medical Faculty,
Istanbul Turkey
Clinical Hemorheology (USA), 1996, 16/3
(271-276)
In this study, we investigated the effect of
ginkgoglycoside in two different doses (19.2
mg/day and 28.8 mg/day) on blood viscosity and
erythrocyte deformability in 27 patients suffering
from cerebrovascular insufficiency. The patients
were divided into two groups randomly consisting
of 13 and 14 patients respectively. Both groups
received 28.8 mg/day ginkgoglycoside between the
1st and 15th day. The first group received the
same dose until the end of the 30th day, whereas
the dose administrated to the second group was
reduced to 19.2 mg/day. In the first group, during
30 days a significant decrease in blood viscosity
and a significant increase in erythrocyte
deformability were observed. In the second group
on the other hand, after dose reduction, the
effect of the drug on blood viscosity and
erythrocyte deformability were diminished.
Improvement of symptoms including vertigo,
tinnutus, headache and forgetfulness in the first
group was found to be significantly different from
the 2nd group at day 30 in a dose dependent
manner.
[Clinical trial of the use of the
combination of piracetam and dihydroergocristine
in vertigo from different causes]
Ordosgoitia H, Castro C, Carbayeda M, Labella
T
An Otorrinolaringol Ibero Am.
1989;16(3):271-9
We report on the therapeutic effect of a
combination of piracetam and dihydroergocristine
in 55 vertiginous patients, of both sexes, between
20 and 67 years of age, from different causes (not
scheduled for surgery). The trial lasted 3 months,
and the drugs were taken twice daily. Aside from
one case who stopped the drug therapy because of
intolerance, the conclusions drawn by the AA. are
seemingly good, both subjectively and objectively
(audiometric and electronystagmographic
tracings).
[Treatment of vertigo syndrome with
Nootropil]
Miszke A, Rapacz K
Otolaryngol Pol (Poland) 1988, 42 (5) p312-7
No abstract.
The use
of piracetam in vertigo.
Fernandes CM; Samuel J
S Afr Med J (South Africa) Nov 23 1985, 68 (11)
p806-8
A pilot study with piracetam (Nootropil; UCB)
was performed in 5 selected dizzy patients who had
a diagnosis of presbyvertigo or vertebrobasilar
insufficiency. The study was monitored by
assessing the effect of piracetam on the
pursuit-tracking system. All patients showed a
remarkable improvement in their pursuit tracking,
in addition to marked subjective improvement in
their vertigo.
The
efficacy of piracetam in vertigo. A double-blind
study in patients with vertigo of central
origin.
Oosterveld WJ.
Arzneimittelforschung. 1980;30(11):1947-9.
In a double-blind trial according to a
switchback design with 4 periods of one week each
a comparison was made between the effects of
piracetam and a placebo. In 22 patients with
vertigo of central origin (posttraumatic,
psychogenic, ecileptogenic and hypertensive
vertigo were excluded) piracetam was found to
significantly reduce symptoms. On anamnestic
examination the patients noted the effect of both
substances on vertigo, motility disturbances,
vitality and sleep. Piracetam was found to have a
significant effect on the first three. The effect
of piracetam is explained by an enhanced control
of the cerebral cortex on the subordinated
vestibular centers, in agreement with findings in
the literature on animal and human
pharmacology.
Piracetam in the treatment of
post-concussional syndrome. A double-blind
study.
Hakkarainen H; Hakamies L
Eur Neurol (Switzerland) 1978, 17 (1) p50-5
The effect of piracetam, a cyclical derivative
of GABA, was compared with that of a placebo in a
double-blind study of 60 patients with
post-concussional syndrome of 2-12 months'
duration. The daily dose of piracetam was 4,800
mg. After 8 weeks of treatment piracetam
significantly reduced the occurrence and severity
of the following symptoms: vertigo, headache,
tiredness, decresed alertness, increased sweating
and neurasthenic symptoms. No significant effect
was observed on the following symptoms: tremor,
orthostatic symptoms, and memory disorders. Side
effect were reported by 64% of the patients under
piracetam and by 32% under placebo. In the
author's opinion, piracetam seems to be a
promising new drug for the treatment of
post-concussional syndrome.
[Evaluation of the therapeutic
effectiveness of a piracetam plus
dihydroergocristine combination in the treatment
of vertigo]
Lopez Martinez R.
Acta Otorrinolaringol Esp. 1988
Jul-Aug;39(4):287-8.
No abstract.
[Hydergine in pathology of the inner
ear]
Jimenez-Cervantes Nicolas J, Amoros Rodriguez
LM
An Otorrinolaringol Ibero Am (1990)
17(1):85-98
There have been treated a total of 20 patients
with troubles on the cochlear compartment and/or
vestibular level which have been clinically
expressed by a perceptive hypoacusia, tinnitus and
rotatory vertigo. The final evaluation is referred
to 17 patients, since three patients do not appear
for control. All patients were treated only with
Hydergine, on doses of 30 drops thrice daily,
which is the equivalent to 4.5 mg/day of active
substance. This treatment remained unaltered till
the end of the last control. Controls have been
effected after 30, 60 and 90 days of starting the
treatment. In each control there was evaluated the
subjective improvement of vertigo, tinnitus and
hypoacusia when effecting to all patients by means
of liminar- supraliminar- and automaticaudiometry,
impedancimetry, T one-decay-test and
electrooculonistagmography. The most meliorated
symptomatology was vertigo, with a global
improvement of 93.7 per cent on the treated
patients. Tinnitus improve by 57.1 per cent and
hypoacusia by 20 per cent. There is a total
correspondence between the subjective data
furnished by the patients and the objective tests
carried out in the successive controls.
[The
elimination of chemotherapy side effects in
pulmonary tuberculosis patients]
Bal'tseva LB; Mel'nik GV; Man'ko VP
Vrach Delo (USSR) Apr 1990, (4) p71-3
Neurotoxic side-effects of tuberculosis
chemotherapy occurred in 14.9% of patients with
tuberculosis treated prophylactically with
intramuscular pyridoxine infusions. Use of small
doses of nootropil (piracetam) allowed to control
the side-effects (headache and vertigo, sleep
disorders, irritation, memory disorders) and to
continue treatment with isoniazide, one of the
most potent tuberculostatic agents.
The
treatment of minocycline-induced brainstem vertigo
by the combined administration of piracetam and
ergotoxin.
Claussen CF, Schneider D, Patil NP
Acta Otolaryngol Suppl (Stockh).
1989;468:171-4.
Two randomized studies to test the efficacy of
a combination of Piracetam and Ergotoxin on the
destabilized brainstem are reported. In the first
study, a pharmacological model using Minocycline
is employed. A follow-up clinical study analysed
the effect of the preparation in 5 patients
suffering from vertigo and other related
complaints. It was seen that there was a
significant improvement in the nystagmus profiles
of the pharmacological model volunteers.
Similarly, the patient group showed a marked
improvement in symptoms, and in orientation
capability as tested by Cranio-Corpo-Graphy.
|